CN111616359A - Health product with radiation-proof function and application thereof - Google Patents
Health product with radiation-proof function and application thereof Download PDFInfo
- Publication number
- CN111616359A CN111616359A CN202010583953.0A CN202010583953A CN111616359A CN 111616359 A CN111616359 A CN 111616359A CN 202010583953 A CN202010583953 A CN 202010583953A CN 111616359 A CN111616359 A CN 111616359A
- Authority
- CN
- China
- Prior art keywords
- radiation
- health product
- health
- product
- mice
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 230000036541 health Effects 0.000 title claims abstract description 45
- 230000005855 radiation Effects 0.000 claims abstract description 39
- 239000000284 extract Substances 0.000 claims abstract description 11
- 241000222336 Ganoderma Species 0.000 claims abstract description 10
- 239000009141 Houttuynia cordata plant extract Substances 0.000 claims abstract description 10
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Chemical compound O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims abstract description 10
- 230000006378 damage Effects 0.000 claims abstract description 9
- 239000008213 purified water Substances 0.000 claims abstract description 9
- 239000012141 concentrate Substances 0.000 claims abstract description 7
- 210000000265 leukocyte Anatomy 0.000 claims description 10
- 210000002798 bone marrow cell Anatomy 0.000 claims description 9
- 150000004676 glycans Chemical class 0.000 claims description 5
- 229920001282 polysaccharide Polymers 0.000 claims description 5
- 239000005017 polysaccharide Substances 0.000 claims description 5
- 241001465754 Metazoa Species 0.000 claims description 4
- 238000002360 preparation method Methods 0.000 claims description 4
- 229930003935 flavonoid Natural products 0.000 claims description 2
- 150000002215 flavonoids Chemical class 0.000 claims description 2
- 235000017173 flavonoids Nutrition 0.000 claims description 2
- 230000004223 radioprotective effect Effects 0.000 claims 1
- 230000000694 effects Effects 0.000 abstract description 17
- 230000003471 anti-radiation Effects 0.000 abstract description 2
- 210000000777 hematopoietic system Anatomy 0.000 abstract description 2
- 241000699670 Mus sp. Species 0.000 description 37
- 238000012360 testing method Methods 0.000 description 25
- 238000000034 method Methods 0.000 description 12
- 241000699666 Mus <mouse, genus> Species 0.000 description 7
- 230000037396 body weight Effects 0.000 description 7
- 239000011049 pearl Substances 0.000 description 7
- 206010018910 Haemolysis Diseases 0.000 description 5
- 238000004458 analytical method Methods 0.000 description 5
- 210000004027 cell Anatomy 0.000 description 5
- 230000008588 hemolysis Effects 0.000 description 5
- 210000002966 serum Anatomy 0.000 description 5
- 238000002474 experimental method Methods 0.000 description 4
- 235000013402 health food Nutrition 0.000 description 4
- 239000000243 solution Substances 0.000 description 4
- 210000001185 bone marrow Anatomy 0.000 description 3
- 238000001514 detection method Methods 0.000 description 3
- 230000002496 gastric effect Effects 0.000 description 3
- 239000000203 mixture Substances 0.000 description 3
- 239000000126 substance Substances 0.000 description 3
- 238000010998 test method Methods 0.000 description 3
- 241000894006 Bacteria Species 0.000 description 2
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 2
- 208000031404 Chromosome Aberrations Diseases 0.000 description 2
- 240000008397 Ganoderma lucidum Species 0.000 description 2
- 235000001637 Ganoderma lucidum Nutrition 0.000 description 2
- 239000012981 Hank's balanced salt solution Substances 0.000 description 2
- 108010006464 Hemolysin Proteins Proteins 0.000 description 2
- 206010028980 Neoplasm Diseases 0.000 description 2
- 240000004808 Saccharomyces cerevisiae Species 0.000 description 2
- 241000607142 Salmonella Species 0.000 description 2
- 241000607768 Shigella Species 0.000 description 2
- 241000191967 Staphylococcus aureus Species 0.000 description 2
- 241000194017 Streptococcus Species 0.000 description 2
- GAMYVSCDDLXAQW-AOIWZFSPSA-N Thermopsosid Natural products O(C)c1c(O)ccc(C=2Oc3c(c(O)cc(O[C@H]4[C@H](O)[C@@H](O)[C@H](O)[C@H](CO)O4)c3)C(=O)C=2)c1 GAMYVSCDDLXAQW-AOIWZFSPSA-N 0.000 description 2
- 229910052785 arsenic Inorganic materials 0.000 description 2
- RQNWIZPPADIBDY-UHFFFAOYSA-N arsenic atom Chemical compound [As] RQNWIZPPADIBDY-UHFFFAOYSA-N 0.000 description 2
- 210000004369 blood Anatomy 0.000 description 2
- 239000008280 blood Substances 0.000 description 2
- 238000004820 blood count Methods 0.000 description 2
- 229910052791 calcium Inorganic materials 0.000 description 2
- 239000011575 calcium Substances 0.000 description 2
- 238000006243 chemical reaction Methods 0.000 description 2
- 231100000005 chromosome aberration Toxicity 0.000 description 2
- 238000013329 compounding Methods 0.000 description 2
- 201000010099 disease Diseases 0.000 description 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 2
- 229930003944 flavone Natural products 0.000 description 2
- 150000002212 flavone derivatives Chemical class 0.000 description 2
- 235000011949 flavones Nutrition 0.000 description 2
- 235000013305 food Nutrition 0.000 description 2
- 239000003228 hemolysin Substances 0.000 description 2
- 230000002949 hemolytic effect Effects 0.000 description 2
- 239000007788 liquid Substances 0.000 description 2
- 239000000463 material Substances 0.000 description 2
- QSHDDOUJBYECFT-UHFFFAOYSA-N mercury Chemical compound [Hg] QSHDDOUJBYECFT-UHFFFAOYSA-N 0.000 description 2
- 229910052753 mercury Inorganic materials 0.000 description 2
- 238000011160 research Methods 0.000 description 2
- 239000007787 solid Substances 0.000 description 2
- 239000000725 suspension Substances 0.000 description 2
- 210000001694 thigh bone Anatomy 0.000 description 2
- VHBFFQKBGNRLFZ-UHFFFAOYSA-N vitamin p Natural products O1C2=CC=CC=C2C(=O)C=C1C1=CC=CC=C1 VHBFFQKBGNRLFZ-UHFFFAOYSA-N 0.000 description 2
- 206010003694 Atrophy Diseases 0.000 description 1
- 241000700199 Cavia porcellus Species 0.000 description 1
- 208000017667 Chronic Disease Diseases 0.000 description 1
- 206010019233 Headaches Diseases 0.000 description 1
- 240000000691 Houttuynia cordata Species 0.000 description 1
- 235000013719 Houttuynia cordata Nutrition 0.000 description 1
- 208000036626 Mental retardation Diseases 0.000 description 1
- 206010027476 Metastases Diseases 0.000 description 1
- 101100460719 Mus musculus Noto gene Proteins 0.000 description 1
- 206010028813 Nausea Diseases 0.000 description 1
- 206010030113 Oedema Diseases 0.000 description 1
- 241001494479 Pecora Species 0.000 description 1
- 208000004880 Polyuria Diseases 0.000 description 1
- 208000000453 Skin Neoplasms Diseases 0.000 description 1
- 206010047700 Vomiting Diseases 0.000 description 1
- 208000031971 Yin Deficiency Diseases 0.000 description 1
- 230000032683 aging Effects 0.000 description 1
- 208000007502 anemia Diseases 0.000 description 1
- 238000010171 animal model Methods 0.000 description 1
- 230000037444 atrophy Effects 0.000 description 1
- 230000001580 bacterial effect Effects 0.000 description 1
- 230000004888 barrier function Effects 0.000 description 1
- 230000033228 biological regulation Effects 0.000 description 1
- 210000000601 blood cell Anatomy 0.000 description 1
- 210000004204 blood vessel Anatomy 0.000 description 1
- 210000004556 brain Anatomy 0.000 description 1
- 238000009395 breeding Methods 0.000 description 1
- 230000001488 breeding effect Effects 0.000 description 1
- 210000005252 bulbus oculi Anatomy 0.000 description 1
- 201000011510 cancer Diseases 0.000 description 1
- 239000006285 cell suspension Substances 0.000 description 1
- 239000003153 chemical reaction reagent Substances 0.000 description 1
- 238000002512 chemotherapy Methods 0.000 description 1
- 239000013078 crystal Substances 0.000 description 1
- 238000007405 data analysis Methods 0.000 description 1
- 230000034994 death Effects 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 230000018109 developmental process Effects 0.000 description 1
- 210000002249 digestive system Anatomy 0.000 description 1
- 239000012895 dilution Substances 0.000 description 1
- 238000010790 dilution Methods 0.000 description 1
- 230000035619 diuresis Effects 0.000 description 1
- 208000002173 dizziness Diseases 0.000 description 1
- 230000002526 effect on cardiovascular system Effects 0.000 description 1
- 230000008011 embryonic death Effects 0.000 description 1
- 210000000750 endocrine system Anatomy 0.000 description 1
- 210000003743 erythrocyte Anatomy 0.000 description 1
- 238000011156 evaluation Methods 0.000 description 1
- 210000003608 fece Anatomy 0.000 description 1
- 210000003754 fetus Anatomy 0.000 description 1
- 239000000835 fiber Substances 0.000 description 1
- 238000011010 flushing procedure Methods 0.000 description 1
- 238000003304 gavage Methods 0.000 description 1
- 230000012010 growth Effects 0.000 description 1
- 230000003394 haemopoietic effect Effects 0.000 description 1
- 231100000869 headache Toxicity 0.000 description 1
- 206010020718 hyperplasia Diseases 0.000 description 1
- 230000036737 immune function Effects 0.000 description 1
- 230000003053 immunization Effects 0.000 description 1
- 238000002649 immunization Methods 0.000 description 1
- 238000001727 in vivo Methods 0.000 description 1
- 230000001939 inductive effect Effects 0.000 description 1
- 230000005764 inhibitory process Effects 0.000 description 1
- 230000005865 ionizing radiation Effects 0.000 description 1
- 208000032839 leukemia Diseases 0.000 description 1
- 201000002364 leukopenia Diseases 0.000 description 1
- 231100001022 leukopenia Toxicity 0.000 description 1
- 230000036244 malformation Effects 0.000 description 1
- 238000005259 measurement Methods 0.000 description 1
- 208000030159 metabolic disease Diseases 0.000 description 1
- 230000009401 metastasis Effects 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 239000011050 natural pearl Substances 0.000 description 1
- 230000008693 nausea Effects 0.000 description 1
- 210000000653 nervous system Anatomy 0.000 description 1
- 238000001543 one-way ANOVA Methods 0.000 description 1
- 230000003287 optical effect Effects 0.000 description 1
- 210000000056 organ Anatomy 0.000 description 1
- 210000005259 peripheral blood Anatomy 0.000 description 1
- 239000011886 peripheral blood Substances 0.000 description 1
- 210000004976 peripheral blood cell Anatomy 0.000 description 1
- 230000002980 postoperative effect Effects 0.000 description 1
- 230000008569 process Effects 0.000 description 1
- 230000000750 progressive effect Effects 0.000 description 1
- 230000002285 radioactive effect Effects 0.000 description 1
- 238000001959 radiotherapy Methods 0.000 description 1
- 210000001034 respiratory center Anatomy 0.000 description 1
- 201000000849 skin cancer Diseases 0.000 description 1
- 210000000952 spleen Anatomy 0.000 description 1
- 238000012430 stability testing Methods 0.000 description 1
- 230000009044 synergistic interaction Effects 0.000 description 1
- 210000001541 thymus gland Anatomy 0.000 description 1
- 231100000331 toxic Toxicity 0.000 description 1
- 230000002588 toxic effect Effects 0.000 description 1
- 230000008673 vomiting Effects 0.000 description 1
- 230000002087 whitening effect Effects 0.000 description 1
Images
Classifications
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
- A23L33/105—Plant extracts, their artificial duplicates or their derivatives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/56—Materials from animals other than mammals
- A61K35/618—Molluscs, e.g. fresh-water molluscs, oysters, clams, squids, octopus, cuttlefish, snails or slugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/06—Fungi, e.g. yeasts
- A61K36/07—Basidiomycota, e.g. Cryptococcus
- A61K36/074—Ganoderma
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/78—Saururaceae (Lizard's-tail family)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/16—Emollients or protectives, e.g. against radiation
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P39/00—General protective or antinoxious agents
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2002/00—Food compositions, function of food ingredients or processes for food or foodstuffs
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Natural Medicines & Medicinal Plants (AREA)
- Chemical & Material Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Engineering & Computer Science (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Mycology (AREA)
- Botany (AREA)
- Epidemiology (AREA)
- Food Science & Technology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Polymers & Plastics (AREA)
- Alternative & Traditional Medicine (AREA)
- Toxicology (AREA)
- Medical Informatics (AREA)
- Nutrition Science (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Biotechnology (AREA)
- Organic Chemistry (AREA)
- Microbiology (AREA)
- General Chemical & Material Sciences (AREA)
- Zoology (AREA)
- Marine Sciences & Fisheries (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Dermatology (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
Abstract
The invention discloses a health care product with an anti-radiation function, wherein each 1000ml of the health care product comprises the following components: 50-70ml of lucid ganoderma extract, 400ml of houttuynia cordata extract, 30-50ml of pearl concentrate and 700ml of purified water, and the health-care product has the effect of eliminating free radicals and can reduce the damage of a hematopoietic system caused by radiation.
Description
Technical Field
The invention relates to the technical field of health-care food, in particular to a health-care product with an irradiation protection function and application thereof.
Background
With the development of global economy, war industry, scientific research and medical treatment, radiation such as nuclear power, radioactive rays and the like seriously damages our health and light people, causes the regulation obstacle of nervous and endocrine systems, leads to the metabolism disorder in vivo, and causes headache, dizziness, nausea, vomiting, leukopenia, anemia and the like; in severe cases, bone marrow is damaged, hematopoietic function is affected, gastrointestinal radiation diseases are caused, digestive system damage occurs, watery stool is generated, even brain radiation diseases are caused, and exhaustion and death of respiratory center and cardiovascular center are rapidly caused. Random injuries which are not directly related to irradiation dose can also occur, and malignant tumors such as leukemia, skin cancer and the like of x-ray workers are obviously higher than those of ordinary people; for example, radiation damage to a fetus can lead to embryonic death, malformation, or even mental retardation. Radiation can also accelerate the aging process, resulting in atrophy of organs, hair whitening, turbid crystals, hyperplasia of intimal fibers of blood vessels, cell chromosome aberration, etc.
At present, people mainly take foods capable of resisting ionizing radiation to reduce the influence of radiation, however, most of health foods sold in the market are unreasonable in formula and poor in radiation protection effect, and the radiation protection effect cannot be obviously achieved.
Therefore, how to provide a health food with a significant anti-radiation effect is a technical problem that needs to be solved urgently by the technical personnel in the field.
Disclosure of Invention
In view of the above, the invention prepares the health food with obvious radiation-resistant effect by compounding the natural pearl concentrated solution, the lucid ganoderma extract and the houttuynia cordata extract.
In order to achieve the purpose, the invention adopts the following technical scheme:
a health product with radiation protection function comprises the following components in every 1000ml of health product: 50-70ml of lucid ganoderma extract, 400ml of houttuynia cordata extract, 30-50ml of pearl concentrated solution and 700ml of purified water.
The technical effect achieved by the technical scheme is as follows: the ganoderma lucidum contains rich ganoderma lucidum polysaccharide, can relieve the inhibition effect of bone marrow function after irradiation, and is characterized in that the content of white blood cells in peripheral blood is increased, the content of DNA in bone marrow is increased, and the damage degree of thymus and spleen is relieved; the houttuynia cordata thunb is mainly used for clearing away heat and toxic materials, and inducing diuresis to reduce edema, and experiments show that the extract liquid can remarkably reduce the chromosome aberration rate and the cell micronucleus rate induced by radiation; the pearl concentrated solution can increase the number of white blood cells in the body of an animal after radiation, thereby having remarkable radiation resistance effect.
Moreover, the health care product has the effects of tonifying qi, nourishing yin and consolidating the constitution by compounding the three components and realizing synergistic interaction among the components, and the research on the efficacy shows that the health care product can improve the immunologic function of an organism, activate the dangerous epidemic system of the organism, improve the activity of SOD, prevent canceration of normal cells, resist the growth and the metastasis of tumors, eliminate free radicals, protect the irradiation harm caused by radiation damage to hematopoietic systems such as marrow and the like, and have better auxiliary curative effects on sub-health, chronic diseases, tumors and qi and yin deficiency after HV postoperative radiotherapy and chemotherapy.
As a preferred technical scheme of the invention, each 1000ml of the health care product comprises the following components in optimal proportion: 60ml of lucid ganoderma extract, 300ml of houttuynia cordata extract, 40ml of pearl concentrate and 600ml of purified water.
As a preferred technical scheme of the invention, the content of crude polysaccharide in each 100ml of the health care product is not less than 461mg, and the content of total flavone is not less than 28.5 mg.
The health care product with the radiation-proof function is applied to preparing a product for resisting radiation hazards.
As a preferred technical scheme, the health care product can improve the content of DNA in bone marrow cells.
As a preferred technical scheme, the health care product can increase the number of white blood cells in an animal body.
The technical effect achieved by the technical scheme is as follows: the health product is used for gastric lavage treatment of mice to obtain60The whole body irradiation is carried out by Co-gamma rays, and the number of leucocytes and the content of DNA of bone marrow cells in the serum of a mouse taking the health care product are found to be obviously higher than those of a mouse not taking the health care product, so that the health care product has obvious auxiliary effect on radiation resistance.
Drawings
FIG. 1 is a preparation process of the health product of the present invention
Detailed Description
The technical solutions in the embodiments of the present invention are clearly and completely described below, and it is obvious that the described embodiments are only a part of the embodiments of the present invention, and not all embodiments. All other embodiments, which can be derived by a person skilled in the art from the embodiments given herein without making any creative effort, shall fall within the protection scope of the present invention.
Example 1
A health product with radiation protection function comprises the following components in every 1000ml of health product: 50ml of lucid ganoderma extract, 200ml of houttuynia cordata extract, 50ml of pearl concentrate and 700ml of purified water.
Example 2
A health product with radiation protection function comprises the following components in every 1000ml of health product: 70ml of lucid ganoderma extract, 400ml of houttuynia cordata extract, 30ml of pearl concentrate and 500ml of purified water.
Example 3
A health product with radiation protection function comprises the following components in every 1000ml of health product: 60ml of lucid ganoderma extract, 300ml of houttuynia cordata extract, 40ml of pearl concentrate and 600ml of purified water.
The health product was prepared according to the procedure of fig. 1, and the prepared health product was subjected to the following experiment:
example 4
A health product with radiation protection function comprises the following components in every 1000ml of health product: 55ml of lucid ganoderma extract, 275ml of houttuynia cordata extract, 45ml of pearl concentrate and 625ml of purified water.
The health product of example 3 was sent to the institute of medical science of Zhejiang province for stability testing, according to GB/T4789.2.3.4.5.10.11.15-2003, GB/T5009.11.12.17.92-2003, pharmacopoeia of people's republic of China 2000 edition (second division), and the samples were left for 0 month, 1 month, 2 months and 3 months to have negative deviations in net content, crude polysaccharide, total flavonoids, calcium, pH, solid matter, arsenic, lead, mercury, total bacterial colony count, coliform bacteria, mold, yeast, salmonella, Shigella, Staphylococcus aureus and hemolytic streptococcus. The judgment basis is Q/JYK 001-2004. The results at 0 month, 1 month, 2 months and 3 months correspond to tables 1-4, respectively;
TABLE 1
TABLE 2
TABLE 3
| Net negative deviation% | 0 | 0 | 0 |
| Crude polysaccharide mg/100ml | 488 | 483 | 494 |
| Total flavone mg/100ml | 29.8 | 30.4 | 29.1 |
| Calcium mg/L | 85.7 | 80.7 | 82.1 |
| pH | 4.45 | 4.49 | 4.52 |
| Solid content% | 3.72 | 3.77 | 3.70 |
| Arsenic mg/L | 0.11 | 0.09 | 0.13 |
| Lead mg/L | 0.43 | 0.43 | 0.41 |
| Mercury mg/L | 0.06 | 0.06 | 0.06 |
| Total number of colonies cfu/ml | <10 | <10 | <10 |
| Coliform bacteria MPN/100ml | <6 | <6 | <6 |
| Mould cfu/ml | <10 | <10 | <10 |
| Yeast cfu/ml | <10 | <10 | <10 |
| Salmonella cfu/ml | Not detected out | Not detected out | Not detected out |
| Shigella cfu/ml | Not detected out | Not detected out | Not detected out |
| Staphylococcus aureus cfu/ml | Not detected out | Not detected out | Not detected out |
| Hemolytic streptococcus cfu/ml | Not detected out | Not detected out | Not detected out |
TABLE 4
The health product in example 3 is sent to the health analysis and detection center of Nanjing medical university for detection, and the detection process and the detection result are as follows:
materials and methods
The test sample, the health product in example 3, brown liquid, 30m 1/bottle, lot number 200404050, was stored in a cool and dry place for testing.
Selecting 60 healthy male mice (approved as SCXK 2003-;
60 healthy male mice 18.6-24.3 are randomly divided into 4 groups, and each group comprises 15 healthy male mice, and the healthy male mice are used as a radiation II group to carry out measurement on the half hemolysis value (HC50) of the serum of the mice;
60 healthy ICR male mice (18.9-24.7 g) were randomly divided into 4 groups of 15 mice each, and the mice were counted as radiation group III.
Dosage-recommended daily intake per person (in terms of 60kg body weight) is 60ml, corresponding to 1ml/d/kg. Three dose groups, namely 5ml/kg.bw and 30ml/kg.bw, are designed according to the recommended intake of human bodies by 5 times, 10 times and 30 times respectively, and a radiation model control group with 0ml/kg.bw is additionally provided, and water (disinfected) is used for replacing a test object. Each functional index was measured by orally administering a corresponding dose of the test substance to mice once a day for 30 days before and after irradiation. The gavage amount of the mice is 10ml/kg.
The main reagents and instruments comprise a Celly HY-318 type blood cell analyzer, an animal balance, an ultraviolet spectrophotometer, a 722 spectrophotometer, Hank's solution, SRBC and guinea pig serum.
The test method comprises the following steps: according to the method for testing the auxiliary protection function of the radiation hazard in the technical specification 2003 edition for the health food test and evaluation.
Peripheral blood cell count: continuously administering the test article 25d with corresponding dose to mice through mouth, wherein the dose group and the radiation model control group are all at the same dose60Co-gamma ray is irradiated once to the whole bodyThe dose was 4Gy, and the mice were continued to be given the corresponding dose of the test substance after irradiation. Mouse orbital blood was collected three times before, 3d after and 14d after irradiation to count leukocytes.
Bone marrow cell DNA content determination: the mice are continuously given the corresponding dose of the test sample 25d by mouth, and the dose group and the radiation model control group are all at the same dose60Co-gamma ray is irradiated once on the whole body, the irradiation dose is 4Gy, and the mouse is continuously given with the corresponding dose of the test object after irradiation. And 3d after irradiation, killing the mice by using a cervical dislocation method, peeling off the thighbone, taking 3ml of Hank's solution, flushing out all bone marrow cells in the thighbone, allowing the cell suspension to pass through an injector with a No. 4 needle so as to fully disperse the cells in the suspension, and measuring the DN A content at a position of 260nm by using an ultraviolet spectrophotometer.
Half maximal hemolysis value (HC)50) And (3) determination: the mice are continuously given the corresponding dose of the test sample 25d by mouth, and the dose group and the radiation model control group are all at the same dose60Co-gamma ray is irradiated once on the whole body, the irradiation dose is 2Gy, and the mouse is continuously given with the corresponding dose of the test object after irradiation. L0d after irradiation, 2% (v/v) Sheep Red Blood Cell (SRBC) suspension is prepared, each mouse is injected with 0.2m1 for immunization, after 5d, the eyeball is removed, blood is taken in a centrifugal tube, the centrifugal tube is placed for lh, centrifuged at 2000r/min for l0min, and serum is separated and collected. After 200-fold dilution of serum, the optical density values of the sample tube and the SRBC at half hemolysis were determined according to the test method. The amount of hemolysin is expressed as half the hemolysin value (HC)50) And (4) showing.
The breeding conditions are that the mice are bred in a barrier system with the temperature of 18-22 ℃ and the relative humidity of 40-70%. The license number SYXK (Su) 2002-0014 is used for experimental animals. The sterilized radiation granulated feed for mice is provided by cooperative medical and biological engineering limited company in Jiangsu province.
And (3) data analysis: SPSS 10.0 software is used for carrying out the homogeneity of variance test on each experiment original data, the data meeting the 'uniform variance' requirement is subjected to statistical treatment by a single-factor variance analysis method and a pairwise comparison method of mean numbers between a plurality of experiment groups and a control group, the data with non-normal distribution or non-uniform variance is subjected to proper variable conversion, and after the 'uniform normal variance' requirement is met, the data obtained by conversion is subjected to statistical treatment.
Results
The effect of the test samples on mouse body weight is shown in tables 5 and 6;
TABLE 5 initial body weights of the groups of mice
As can be seen from table 5, the initial body weights of the mice were again compared between the 5ml/kg.bw, 10ml/kg.bw, 30ml/kg.bw groups and the 0ml/kg.bw group, with no significant difference (p > 0.05). I.e. the initial body weight of the mice was more balanced between the groups.
TABLE 5 terminal body weight of mice in each group
As can be seen from table 6, it is,60before Co-gamma ray irradiation, the mice are orally given to a test sample 25d with different doses, the body weight of each dose group of mice is subjected to normality and homogeneity of variance tests to meet the requirements of normality and homogeneity of variance, a one-factor variance analysis method and a pairwise comparison method of mean values between a plurality of experimental groups and a control group are used for statistical treatment, and the results show that compared with a group of 5ml/kg.Bw, 10ml/kg.Bw and 30m1/kg.bw, the differences are not significant (p is the difference of the groups of 0 ml/kg.bw)>0.05)。
The effect of the test samples on the total number of leukocytes in the irradiated mice is shown in table 7;
TABLE 7 Effect of test samples on the Total white blood cell count in mice
60Different doses were given orally to mice before and after Co-gamma irradiationThe total number of irradiated leukocytes measured by the donation board Zhenling mixture 40d is subjected to the homogeneity test of variance to meet the requirement of homogeneity of variance, and statistical treatment is carried out by a single-factor variance analysis method and a pairwise comparison method of mean numbers between a plurality of experimental groups and a control group. And (5) carrying out normal and variance homogeneity tests on the total number of the white blood cells of the mice at 3d after irradiation and 14d after irradiation, wherein the normal and variance homogeneity tests do not meet the requirements of normal and variance homogeneity, and carrying out statistical treatment by using a rank sum test method. As can be seen from the results in Table 7, the total number of leukocytes was significantly higher in the 14d 30m1/kg. bw group mice than in the 0ml/kg. bw group after irradiation (p<0.01)。
The influence of the test sample on the DNA content of the bone marrow cells of the irradiated mice is shown in Table 8;
TABLE 8 influence of test samples on the DNA content of bone marrow cells of mice after irradiation
60Before and after Co-gamma ray irradiation, the mice are orally given with different doses of the mixture 28d of folk-tablet Zhenling, the DNA content of the bone marrow cells of the mice of each dose group is tested for normality and variance homogeneity, the normal requirement is met, and statistical treatment is carried out by a single-factor variance analysis method and a pairwise comparison method of mean numbers between a plurality of experimental groups and a control group. From the results in Table 8, it can be seen that the DNA content of the gastric pulp cells of mice in the 5ml/kg.bw group, the 10ml/kg.bw group and the 30m1/kg.bw group is significantly higher than that in the 0ml/kg.bw group.
Half hemolysis value HC of the irradiated mice50See table 9;
TABLE 9
60Before and after Co-gamma ray irradiation, the mice are orally given with different doses of the mixture of folk-tablet Zhenling 40d, and the half hemolysis value of the mice of each dose group is tested for the homogeneity of variance, so that the homogeneity of variance is satisfiedStatistical treatment is required to be carried out by a one-way anova method and a pairwise comparison method of mean values between a plurality of experimental groups and a control group. As can be seen from the results in Table 9, the differences were not significant in the 5ml/kg.Bw, 10ml/kg.Bw, 30m1/kg.bw groups compared with the 0ml/kg.bw group (p)>0.05)。
From the above results, it can be seen that one shot irradiation was used60The effect of the health product of example 3 on the auxiliary protection of radiation hazard was evaluated by Co-gamma ray method. The test substance 25d is continuously administered with 5ml/kg. Bw, 10m1/kg. Bw, 30m1/kg. bw dosage, and irradiated once60Co-gamma radiation, and the subject is administered continuously after irradiation. The results showed that the test sample was irradiated to mice in the 30m1/kg.bw group60The total number of leucocytes after 14 days of Co-gamma rays is obviously higher than that of the group of 0 ml/kg.bw; the DNA content of the mouse bone marrow cells in the 5ml/kg.bw group, the 10ml/kg.bw group and the 30m1/kg.bw group is obviously higher than that in the 0ml/kg.bw group. Therefore, the tested sample is considered to have an auxiliary protection function against radiation hazards.
The embodiments in the present description are described in a progressive manner, each embodiment focuses on differences from other embodiments, and the same and similar parts among the embodiments are referred to each other.
The previous description of the disclosed embodiments is provided to enable any person skilled in the art to make or use the present invention. Various modifications to these embodiments will be readily apparent to those skilled in the art, and the generic principles defined herein may be applied to other embodiments without departing from the spirit or scope of the invention. Thus, the present invention is not intended to be limited to the embodiments shown herein but is to be accorded the widest scope consistent with the principles and novel features disclosed herein.
Claims (6)
1. A health product with radiation protection function is characterized in that each 1000ml of the health product comprises the following components: 50-70ml of lucid ganoderma extract, 400ml of houttuynia cordata extract, 30-50ml of pearl concentrated solution and 700ml of purified water.
2. The radiation-proof health product of claim 1, wherein each 1000ml of the health product comprises the following components: 60ml of lucid ganoderma extract, 300ml of houttuynia cordata extract, 40ml of pearl concentrate and 600ml of purified water.
3. The health product with radiation protection function of claim 2, wherein the content of crude polysaccharide is not less than 461mg and the content of total flavonoids is not less than 28.5mg per 100ml of health product.
4. Use of a health product with radiation protection function according to any one of claims 1-3 in the preparation of a product for protecting against radiation hazards.
5. The use of the radiation protection health product of claim 4 in the preparation of a radiation hazard resistant product, wherein the health product can assist in increasing the DNA content in bone marrow cells.
6. The use of a health product with radioprotective effect in the preparation of a product for resisting radiation damage according to claim 4, wherein the health product can assist in increasing the number of leukocytes in an animal.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN202010583953.0A CN111616359A (en) | 2020-06-23 | 2020-06-23 | Health product with radiation-proof function and application thereof |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN202010583953.0A CN111616359A (en) | 2020-06-23 | 2020-06-23 | Health product with radiation-proof function and application thereof |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN111616359A true CN111616359A (en) | 2020-09-04 |
Family
ID=72267656
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN202010583953.0A Pending CN111616359A (en) | 2020-06-23 | 2020-06-23 | Health product with radiation-proof function and application thereof |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN111616359A (en) |
Citations (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN1436538A (en) * | 2002-02-07 | 2003-08-20 | 杜宪明 | Effervescent pearl calcium tablet and its prepn process |
| CN101168047A (en) * | 2007-10-24 | 2008-04-30 | 珍奥集团股份有限公司 | Composition with radiation-proof, anti-oxidation and DNA-protection effects and use |
| CN102150771A (en) * | 2011-03-18 | 2011-08-17 | 杭州碧于天保健品有限公司 | Anti-radiation bee product composite preparation and preparation method thereof |
| CN104522806A (en) * | 2014-12-24 | 2015-04-22 | 百花医药集团股份有限公司 | Herba houttuyniae healthcare beverage and preparation method thereof |
| CN106562407A (en) * | 2015-10-12 | 2017-04-19 | 杨芳 | Health-care food with antioxidant function |
| CN109924474A (en) * | 2019-04-04 | 2019-06-25 | 上海禾向健康科技发展有限公司 | A kind of composition of radiation protection, ganoderma lucidum tea polyphenols health food and preparation method thereof |
-
2020
- 2020-06-23 CN CN202010583953.0A patent/CN111616359A/en active Pending
Patent Citations (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN1436538A (en) * | 2002-02-07 | 2003-08-20 | 杜宪明 | Effervescent pearl calcium tablet and its prepn process |
| CN101168047A (en) * | 2007-10-24 | 2008-04-30 | 珍奥集团股份有限公司 | Composition with radiation-proof, anti-oxidation and DNA-protection effects and use |
| CN102150771A (en) * | 2011-03-18 | 2011-08-17 | 杭州碧于天保健品有限公司 | Anti-radiation bee product composite preparation and preparation method thereof |
| CN104522806A (en) * | 2014-12-24 | 2015-04-22 | 百花医药集团股份有限公司 | Herba houttuyniae healthcare beverage and preparation method thereof |
| CN106562407A (en) * | 2015-10-12 | 2017-04-19 | 杨芳 | Health-care food with antioxidant function |
| CN109924474A (en) * | 2019-04-04 | 2019-06-25 | 上海禾向健康科技发展有限公司 | A kind of composition of radiation protection, ganoderma lucidum tea polyphenols health food and preparation method thereof |
Non-Patent Citations (2)
| Title |
|---|
| 蒲晓璐等: "具有抗辐射作用的食品及其研究现状", 《农产品加工(创新版)》 * |
| 邓家刚 等: "《广西道地药材》", 31 January 2007, 中国中医药出版社 * |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2015529670A (en) | Chinese medicine composition for regulating immunity and method for producing the same | |
| CN103800661B (en) | A kind of enhancing immunity, alleviating physical fatigue compositions and containing its preparation | |
| CN101209297A (en) | Compound Chinese medicinal granule for treating chicken coccidiosis | |
| CN101744924B (en) | Multiple-effect Chinese herbal medicine compound of bacterial diseases of turbot | |
| JP2011526255A (en) | Natural allicin tablet and preparation method thereof | |
| CN103169737A (en) | Composite of Antrodia camphorata entity and shell-broken ganoderma lucidum spore powder and application thereof in immune adjustment | |
| CN102389559B (en) | Traditional Chinese medicine composition and application as radiotherapy sensitizer | |
| Abouelella et al. | Phytotherapeutic effects of Echinacea purpurea in gamma-irradiated mice | |
| CN111616359A (en) | Health product with radiation-proof function and application thereof | |
| CN1089000C (en) | 'Sanhuangqinbao' powder-medicine for chicken | |
| CN109381514B (en) | Scutellaria baicalensis extract, composition thereof and application of scutellaria baicalensis extract in radiation injury protection | |
| CN102048059A (en) | Feed additive used for preventing and treating vibrio gill-rot disease of aquatic animals and preparation method thereof | |
| CN102100729B (en) | Oral administration medicament for treating and preventing radiation damage | |
| CN107029040B (en) | Compound traditional Chinese medicine powder for treating cow subclinical mastitis | |
| CN101229362B (en) | Use of thymulin on preparing protective medicine of antineoplastic agent, tumour physiatry and chemotherapeutic medicine | |
| CN100348259C (en) | Medicine composition for raising immunity and its prepn and application | |
| CN1421238A (en) | Natural bioreaction regulator with the functions of resisting cancer, resisting free radical damage and regulating immunity | |
| CN103845524B (en) | It is a kind of to treat the Chinese medicine composition and preparation method and purposes that kidney essence deficiency is demonstrate,proved after tumor radiotherapy, chemotherapy | |
| CN103191268B (en) | Traditional Chinese medicinal composition for treating lung cancer | |
| CN1593554A (en) | Medicine for treating diseases of respiratory system | |
| KR101359528B1 (en) | Radiation protective composition comprising effective bee-venom and royal jelly | |
| CN112220887A (en) | Traditional Chinese medicine composition for improving immunity and preparation method thereof | |
| Wang | Experimental Research and Analysis of Hedysari Total Polysaccharides in Vivo Mice Antineoplastic | |
| CN1911258A (en) | Extractive of parasitic loranthus, prepn. method and application thereof | |
| CN104873547B (en) | A kind of pharmaceutical composition and preparation and purposes |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PB01 | Publication | ||
| PB01 | Publication | ||
| SE01 | Entry into force of request for substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| RJ01 | Rejection of invention patent application after publication | ||
| RJ01 | Rejection of invention patent application after publication |
Application publication date: 20200904 |